Actuate Therapeutics Reports Positive Phase II Data In Salivary Gland Cancers

Actuate Therapeutics reported positive Phase II results for elraglusib combined with carboplatin or cisplatin in advanced metastatic salivary gland cancers (47% ACC, 53% non‑ACC), showing median overall survival of 18.6 months (58% alive at 1 year, 40% at 2 years), median PFS of 6.4 months with 27% progression‑free at 1 year, and a 27.8‑month median OS in the non‑ACC cohort; the data were published in Clinical Cancer Research. While PFS is modest overall, it compares favorably versus historical PFS of under 6 months for non‑ACC but is short of the 49‑month historical PFS cited for ACC, suggesting a stronger signal in non‑ACC patients and a mixed efficacy picture by subtype. Actuate shares rose more than 4% in pre‑market trading following the report.

Analysis

Actuate Therapeutics reported Phase II data for elraglusib combined with carboplatin or cisplatin in advanced metastatic salivary gland cancers (47% ACC, 53% non‑ACC), showing a median overall survival (OS) of 18.6 months with 58% alive at 1 year and 40% at 2 years, a non‑ACC median OS of 27.8 months, and a median progression‑free survival (PFS) of 6.4 months with 27% progression‑free at 1 year; the results were published in Clinical Cancer Research. The efficacy signal appears concentrated in the non‑ACC cohort where OS compares favorably to the cited historical PFS of under 6 months for non‑ACC, while the ACC subgroup trails the historical PFS figure of 49 months, producing a mixed efficacy profile by subtype. Interpretation is limited by Phase II sample size and reliance on historical comparators, leaving uncertainty on durability, safety, and generalizability that require randomized confirmation. Market reaction was modestly positive—shares rose more than 4% pre‑market after a $7.52 close—consistent with the mildly positive sentiment and a low-to-moderate projected market impact, making near‑term upside contingent on clear next‑stage trial design, safety readouts, or partnering/regulatory developments.

Key Decisions for Investors

• For risk-tolerant, event-driven investors consider a small, speculative position to capture upside if follow‑on randomized trials or partnering announcements are confirmed,
• Monitor key near-term catalysts closely—announcements of larger randomized trials, safety/durability data and any regulatory or partnering news—as these will materially re-rate risk/return,
• Limit position size or hedge exposure until confirmatory data are available given mixed subtype efficacy, small Phase II cohort, and reliance on historical comparators